XML 45 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1

Collaboration Agreements,License Agreement and Revenues (Tables)

12 Months Ended

Dec. 31, 2021

Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue and Product Revenue Net

Product revenue, net from the sales of roxadustat commercial product in China was as follows (in thousands):

		Years Ended December 31,
		2021				2020				2019
Direct Sales:
Gross revenue		$	13,727			$	89,027				2,803
Price adjustment			(982	)			—				(936	)
Non-key account hospital listing award			95				(9,325	)			—
Contractual sales rebate			(832	)			(6,189	)			(149	)
Other discounts and rebates			(21	)			(923	)			(18	)
Sales returns			83				(92	)			—
Direct sales revenue, net			12,070				72,498				1,700
Sales to Falikang:
Gross transaction price			97,531				—				—
Profit share			(34,759	)			—				—
Net transaction price			62,772				—				—
Increase in deferred revenue			(27,204	)			—				—
Sales to Falikang revenue, net			35,568				—				—
Total product revenue, net		$	47,638			$	72,498			$	1,700

Summary of Amounts Recognized as Revenue

Amounts recognized as revenue under the Eluminex were as follows (in thousands):

				Years Ended December 31,
Agreement		Performance Obligation		2021				2020				2019
Eluminex		License revenue		$	8,000			$	—			$	—

Roll-forward of Related Contract Liabilities

The following table includes a roll-forward of the related contract liabilities (in thousands):

		Balance at December 31, 2020				Additions				Deduction				Currency Translation and Other				Balance at December 31, 2021
Product revenue - Direct sales - contract liabilities		$	(15,137	)		$	(1,371	)		$	13,645			$	(313	)		$	(3,176	)

Schedule of Drug Product Revenue

Drug product revenue was as follows (in thousands):

		Years Ended December 31,
		2021				2020				2019
Astellas		$	3,186			$	4,281			$	(36,324	)
AstraZeneca			(2,224	)			4,625				—
Drug product revenue		$	962			$	8,906			$	(36,324	)

AstraZeneca Agreements [Member]

Roll-forward of Related Contract Liabilities

The following table includes a roll-forward of the related deferred revenue that is considered as a contract liability (in thousands):

		Balance at December 31, 2020				Additions				Recognized as Revenue				Balance at December 31, 2021
Product revenue - AstraZeneca China    performance obligation - deferred revenue		$	(137,338	)		$	(69,746	)		$	35,568			$	(171,516	)

Drug Product Revenue [Member]

Roll-forward of Related Contract Liabilities

The following table includes a roll-forward of the above-mentioned deferred revenues that are considered as contract liabilities related to drug product (in thousands):

		Balance at December 31, 2020				Additions				Recognized as Revenue				Balance Presented Net Against Contract Asset				Balance at December 31, 2021
Astellas - Japan Agreement		$	—			$	(1,974	)		$	—			$	—			$	(1,974	)
Astellas - Europe Agreement			(5,984	)			(69,874	)			179				49,788				(25,891	)
AstraZeneca - U.S. Agreement			—				(11,171	)			—				—				(11,171	)
Drug product revenue - deferred revenue		$	(5,984	)		$	(83,019	)		$	179			$	49,788			$	(39,036	)

Japan [Member]

Summary of License Revenue and Development Revenue Recognized under Agreement

Amounts recognized as license revenue and development revenue under the Japan Agreement with Astellas were as follows (in thousands):

				Years Ended December 31,
Agreement		Performance Obligation		2021				2020				2019
Japan		License revenue		$	—			$	14,323			$	11,935
		Development revenue		$	248			$	1,220			$	1,222

Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue and Product Revenue Net

The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Japan Agreement with Astellas, along with any associated deferred revenue as follows (in thousands):

Japan Agreement		Cumulative Revenue Through December 31, 2021				Deferred Revenue at December 31, 2021				Total Consideration Through December 31, 2021
License		$	100,347			$	—			$	100,347
Development revenue			16,598				—				16,598
Total license and development    revenue		$	116,945			$	—			$	116,945

Europe [Member]

Summary of License Revenue and Development Revenue Recognized under Agreement

Amounts recognized as license revenue and development revenue under the Europe Agreement with Astellas were as follows (in thousands):

				Years Ended December 31,
Agreement		Performance Obligation		2021				2020				2019
Europe		License revenue		$	108,434			$	—			$	117,470
		Development revenue		$	21,679			$	17,954			$	28,172

Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue and Product Revenue Net

The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Europe Agreement with Astellas, along with any associated deferred revenue as follows (in thousands):

Europe Agreement		Cumulative Revenue Through December 31, 2021				Deferred Revenue at December 31, 2021				Total Consideration Through December 31, 2021
License		$	596,385			$	—			$	596,385
Development revenue			270,641				—				270,641
Total license and development    revenue		$	867,026			$	—			$	867,026

U.S./RoW and China [Member]

Summary of License Revenue and Development Revenue Recognized under Agreement

Amounts recognized as license revenue and development revenue under the U.S./RoW and China Agreements with AstraZeneca were as follows (in thousands):

				Years Ended December 31,
Agreement		Performance Obligation		2021				2020				2019
U.S. / RoW and China		License revenue		$	—			$	—			$	47,681
		Development revenue			48,345				61,508				84,629
		China performance obligation		$	—			$	(90	)		$	90

Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue and Product Revenue Net

The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the U.S./RoW Agreement and China Agreement, along with any associated deferred revenue as follows (in thousands):

U.S. / RoW and China Agreements		Cumulative Revenue Through December 31, 2021				Deferred Revenue at December 31, 2021				Total Consideration Through December 31, 2021
License		$	341,844			$	—			$	341,844
Co-development, information sharing &   committee services			603,119				—				603,119
China performance obligation *			35,568				171,516				207,084
Total license and development    revenue		$	980,531			$	171,516		**	$	1,152,047

* China performance obligation revenue is recognized as product revenue, as described in details under Product Revenue, Net section below.

** Contract assets and liabilities related to rights and obligations in the same contract are recorded net on the consolidated balance sheets. As of December 31, 2021, deferred revenue included $162.4 million related to the U.S./RoW and China Agreement, which represents the net of $171.5 million of deferred revenue presented above and a $9.1 million unbilled co-development revenue under the China Amendment with AstraZeneca.

X

- Definition

Contract with customer milestone method.

+ References

No definition available.

+ Details

Name:	fgen_ContractWithCustomerMilestoneMethodTableTextBlock
Namespace Prefix:	fgen_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Schedule of drug product revenue.

+ References

No definition available.

+ Details

Name:	fgen_ScheduleOfDrugProductRevenueTableTextBlock
Namespace Prefix:	fgen_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765

+ Details

Name:	us-gaap_DeferredRevenueByArrangementDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=fgen_DrugProductRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=country_JP
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: